Prostatitis

Overactive Bladder Market Spotlight Report 2021: High-impact Upcoming Events for drugs in the Space Comprise Topline Phase III Trial Results for Gemtesa, and an Estimated PDUFA Date for Myrbetriq - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Pharmaceutical, Health, Clinical Trials, Risk, Patient, SNARE (protein), Arthritis, SNARE, Probability, Urinary tract infection, Sleep apnea, Woman, Prevalence, Pfizer, Man, Disease, Degenerative disease, Nocturia, Irritable bowel syndrome, Joint, UTI, Hypertension, Overactive bladder, Depression, Ageing, Clinical trial, Quality of life, Prostatitis, PDUFA, Incontinence, Dietary supplement, Medical imaging, Pharmaceutical industry, Urinary bladder

Prevalence and symptom severity increase with age, and the symptoms of overactive bladder persist for years in the majority of patients.

Key Points: 
  • Prevalence and symptom severity increase with age, and the symptoms of overactive bladder persist for years in the majority of patients.
  • The approved drugs in the overactive bladder space target the calcium channel, muscarinic acetylcholine receptor, SNARE proteins, and beta-3 adrenergic receptor.
  • The largest proportion of industry-sponsored drugs in active clinical development for overactive bladder are in Phase II, with no drugs in Phase III.
  • High-impact upcoming events for drugs in the overactive bladder space comprise topline Phase III trial results for Gemtesa, and an estimated PDUFA date for Myrbetriq.

Prostate Health Markets, 2026: Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Health, Oncology, CAGR, Patient, Chemotherapy, Man, Inflammation, Cancer vaccine, Pfizer, Prostate, Incidence, Prostate cancer, GlaxoSmithKline, Population, Growth, Tamsulosin, NA, Benign prostatic hyperplasia, BPH, OTC, Merck & Co., C1-inhibitor, USD, Risk, Male, Eli Lilly and Company, Medical imaging, Health insurance, Pharmaceutical industry, Prostatitis

The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer.
  • Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis.
  • In 2020, prostate cancer accounted for the largest share in the prostate health market.

Studies Correlate Overactive Bladder Onset After A COVID-19 Diagnosis

Retrieved on: 
Friday, September 10, 2021

Two new studies being presented this year at the American Urological Association's 2021 Annual Meeting demonstrate the relationship between COVID-19 and the onset of or worsening of symptoms of Overactive Bladder (OAB).

Key Points: 
  • Two new studies being presented this year at the American Urological Association's 2021 Annual Meeting demonstrate the relationship between COVID-19 and the onset of or worsening of symptoms of Overactive Bladder (OAB).
  • Due to the paucity of data regarding genitourinary symptoms in COVID-19, this study set out to investigate the disease manifestation(s) in bladder function.
  • We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19 Associated Cystitis (CAC).
  • METHODS: We used AUA Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients at our urban-located institution from 5/22/2020 to 12/31/2020.